---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-23-000042"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:17:17.776962+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Akebia Q3 net loss $14.5M, Auryxia rev $40.1M, vadadustat PDUFA Mar 27, 2024

## Summary
- Net loss improved to $14.5M from $54.1M in Q3 2022; total revenue $42.0M, down from $48.7M.
- Auryxia net product revenue $40.1M (Q3 2022: $42.0M); FY 2023 guidance reaffirmed at $170-175M.
- Vadadustat NDA resubmission accepted; PDUFA date set for March 27, 2024 for anemia in dialysis CKD.
- Vadadustat approved in 36 countries including Australia and Taiwan; five posters at Kidney Week 2023.
- Modified Pharmakon loan: principal payments deferred to Oct 2024, maturity extended to March 2025.

## SEC filing metadata
- accession: 0001517022-23-000042
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000042/0001517022-23-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000042/akba-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-23-000042
- JSON: https://secwatch.observer/filing/0001517022-23-000042.json
- Plain text: https://secwatch.observer/filing/0001517022-23-000042.txt

## Key facts
- Earnings Releases
  Akebia Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $42.0 million, net income $14.5 million. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2023
  - Revenue: $42.0 million
  - Net income: $14.5 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenues were $42.0 million for the third quarter of 2023, compared to $48.7 million for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000042/0001517022-23-000042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.